Interferon β(IFN-β) is a well-known disease-modifying therapy designed for relapsing remitting MS(RRMS), the possible mechanism of which includes the increased number of CD56bright NK cells after treatment [74, 75]. The gene discussed is IFNB1; the disease is relapsing-remitting multiple sclerosis.